205 related articles for article (PubMed ID: 21057205)
1. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
[TBL] [Abstract][Full Text] [Related]
2. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
3. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
4. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
O'Neill AJ; Prencipe M; Dowling C; Fan Y; Mulrane L; Gallagher WM; O'Connor D; O'Connor R; Devery A; Corcoran C; Rani S; O'Driscoll L; Fitzpatrick JM; Watson RW
Mol Cancer; 2011 Oct; 10():126. PubMed ID: 21982118
[TBL] [Abstract][Full Text] [Related]
5. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
[TBL] [Abstract][Full Text] [Related]
6. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Lin JZ; Zhu JG; Wu HF; Li JM; DE W; Wang ZJ
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):302-308. PubMed ID: 29714413
[TBL] [Abstract][Full Text] [Related]
7. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
9. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of GRIM-19 augments the sensitivity of prostate cancer cells to docetaxel by targeting Rad23b.
Lin H; Shen Z; Liu H; Yang M; Lin J; Luo L; Liu L; Chen H
Clin Exp Pharmacol Physiol; 2020 Jan; 47(1):76-84. PubMed ID: 31531888
[TBL] [Abstract][Full Text] [Related]
11. Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.
Mimeault M; Johansson SL; Batra SK
Br J Cancer; 2013 Mar; 108(5):1079-91. PubMed ID: 23449353
[TBL] [Abstract][Full Text] [Related]
12. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
13. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.
Mediavilla-Varela M; Pacheco FJ; Almaguel F; Perez J; Sahakian E; Daniels TR; Leoh LS; Padilla A; Wall NR; Lilly MB; De Leon M; Casiano CA
Mol Cancer; 2009 Aug; 8():68. PubMed ID: 19715609
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
Li Y; Hong X; Hussain M; Sarkar SH; Li R; Sarkar FH
Mol Cancer Ther; 2005 Mar; 4(3):389-98. PubMed ID: 15767548
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.
Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Gul MK; Erten C; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
Mol Biol Rep; 2010 Mar; 37(3):1269-77. PubMed ID: 19288219
[TBL] [Abstract][Full Text] [Related]
18. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
Shi GH; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Xiao WJ; Ma CG
Acta Pharmacol Sin; 2010 Jul; 31(7):867-73. PubMed ID: 20581857
[TBL] [Abstract][Full Text] [Related]
19. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
[TBL] [Abstract][Full Text] [Related]
20. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]